SEC Filing Summary
Filing and period: The document is Retrophin, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, with quarterly results for Q4. The request metadata identifies Travere Therapeutics, Inc.; the filing itself names Retrophin, Inc., so verify the issuer and filing match.
Business context
Retrophin was a rare-disease biopharmaceutical company with three marketed products—Thiola, Cholbam and Chenodal—and a clinical pipeline led by fosmetpantotenate and sparsentan. It also funded Censa’s CNSA-001 program and held rights to liquid ursodeoxycholic acid (L-UDCA).
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Net product sales | $164.2 million | $154.9 million |
| Operating expenses | $244.3 million | $208.7 million |
| Operating loss | $80.0 million | $53.8 million |
| Net loss | $102.7 million | $59.7 million |
| Operating cash flow | $(25.0) million | $7.4 million |
| Cash and marketable securities, year-end | $471.5 million | $300.6 million |
| Working capital, year-end | $391.1 million | $240.1 million |
FY 2018 gross profit was approximately $158.7 million, or a 96.6% gross margin, based on net product sales less cost of goods sold. Operating margin was approximately negative 48.7%. The filing reports a 4.74 working-capital ratio, versus 3.80 in 2017.
Q4 2018 net product sales were $43.8 million, operating loss was $5.0 million and net loss was $7.5 million. In Q4 2017, sales were $42.2 million, operating loss was $15.2 million and net loss was $17.6 million.
At year-end, debt principal was approximately $298.6 million: $276 million of 2.50% convertible notes due 2025 and $22.6 million remaining on 4.5% notes due May 2019. The balance-sheet carrying value of convertible debt was approximately $217.5 million, net of discounts and issuance costs. FY 2018 interest expense was $9.8 million. The filing states available cash and short-term investments were expected to fund operations in the near term.
Material changes versus prior period
- Annual sales increased 6.0%, attributed to higher patient counts across products; Thiola sales were $89.2 million and bile-acid product sales were $75.1 million.
- Research and development expense rose $45.6 million to $123.8 million, reflecting activity in the sparsentan, fosmetpantotenate and CNSA-001 programs. SG&A increased modestly to $103.7 million.
- Net loss widened by $42.9 million. The year included a $17.0 million loss on early extinguishment of 2019 notes, following a $40.2 million cash repurchase of $23.4 million principal using proceeds from the 2025 note offering.
- Cash and marketable securities rose by $170.9 million, principally following the 2025 note issuance. Operating cash flow moved from positive $7.4 million to negative $25.0 million.
Outlook, risks and unusual items
- Management expected FY 2019 R&D expense to increase as clinical programs advanced. Top-line fosmetpantotenate Phase 3 FORT data were expected in Q3 2019; sparsentan FSGS interim data in the second half of 2020; sparsentan IgAN primary-endpoint data in the first half of 2022; and CNSA-001 Phase 2 data in Q2 2019.
- The Thiola reformulation had an FDA target action date of June 30, 2019. Management was also pursuing a Chenodal indication for CTX and development of L-UDCA.
- Key uncertainties include clinical-trial results and enrollment, FDA/EMA acceptance of proteinuria as a basis for accelerated or conditional approval, reimbursement and pricing pressure, generic or compounded competition, and reliance on sole-source manufacturers and a third-party distributor.
- Spring Pharmaceuticals sued Retrophin and others in October 2018, alleging antitrust and unfair competition related to access to Thiola samples for generic bioequivalence testing. Retrophin said it intended to defend the case. Other litigation includes arbitration involving former CEO Martin Shkreli and a dispute over advancement and potential reimbursement of his legal fees.
- Retrophin had paid Censa $10 million for the option and $5 million for a milestone, and expected to fund approximately $17 million through proof of concept. Exercising the acquisition option would require $65 million upfront, subject to terms, plus up to $25 million in milestone payments.
- The filing reports effective disclosure controls and internal control over financial reporting, and an unqualified audit opinion. Management cautioned that cash needs depend on operating results, development costs and access to financing.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Retrophin, Inc., while the request metadata says Travere Therapeutics, Inc.
- Review the full audited statements and debt-note terms, especially the 2019 maturity, conversion and repurchase provisions, and total future contractual commitments.
- Track marketed-product sales, payer rebates, generic competition and the outcome of the Thiola sample-access litigation.
- Check actual results against the stated clinical-data timelines and assess whether trial endpoints support regulatory filings or approvals.
- Assess the cash burn, financing runway, contingent consideration, and potential costs of the Censa option and other development commitments.